XML 100 R62.htm IDEA: XBRL DOCUMENT v3.25.0.1
Significant agreements - Novartis Collaboration Agreement - Accounting Analysis (Details) - Novartis
$ in Thousands
1 Months Ended
Mar. 27, 2023
USD ($)
item
Nov. 30, 2024
USD ($)
Significant agreements.    
Transaction price $ 50,000 $ 53,000
Amount of estimate of variable consideration   $ 3,000
Two combined performance obligations for the first and second targets comprised of the Novartis Research License and the related research and development services during the research term for the first and second targets    
Significant agreements.    
Combined performance obligations | item 2  
Transaction price $ 18,008  
Two material rights associated with limited substitution rights    
Significant agreements.    
Number of material rights | item 2  
Transaction price $ 2,466  
Two material rights associated with options to progress development candidates incorporating radionuclides    
Significant agreements.    
Number of material rights | item 2  
Transaction price $ 19,684  
Two material rights associated with options to progress development candidates not incorporating radionuclides    
Significant agreements.    
Number of material rights | item 2  
Transaction price $ 9,842